Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “CLIMACTERIC”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed2000

[Influence of the phytoestrogen drug, SoyaVital, on climacteric symptoms].

The results of phytoestrogen drug SoyaVital on the climacteric symptoms are presented. The preparation consists of 35 mg isoflavones with high content of genistein in one capsule. A group of 26 patients having climacteric symptoms have been treated by one capsule per day for a period of 12 weeks. The evaluation of the symptoms by Kuppermann score decreased statistically significant by 30.06%. The authors recommend SoyaVital as an alternative to the hormonal replacement therapy.

Administration, Oral↗
PubMed2000

[Bone densitometry and uterine size: a practical relationship for climacteric women].

BACKGROUND: Double beam bone densitometry allows to select climacteric women who will benefit from hormone replacement. However, it is not always affordable in clinical practice. AIM: To study possible alternative markers of bone mineral density. PATIENTS AND METHODS: A retrospective survey of climacteric women in whom bone mineral density was measured when hormone replacement therapy was started. Eighty one women were studied and in 27, uterine size index was obtained from pelvic ultrasound examinations. Women with and without uterine size index measurements were analyzed separately. Relationships of bone mineral density with age, lapse from menopause, body mass index and uterine size index were sought. RESULTS: There was a significant regression between the lapse in years from menopause and lumbar bone mineral density in the group without uterine size index measurements (r2 = 0.228, ANOVA p = 0.014). There was also a significant regression of lumbar bone mineral density with the uterine size index (r2 = 0.236, ANOVA p = 0.01) in those women in whom this measurement was available. No other variables were associated with bone mineral density. CONCLUSION: In this group of patients, the lapse after menopause and uterine size index are predictors of lumbar bone mineral density (Rev Méd Chile 2000; 128: 1127-31).

Adult↗
PubMed2001

[The effect of hormonal replacement therapy on symptoms of climacteric syndrome and selected metabolic parameters].

GOAL OF STUDY: The goal of this paper was estimation of influence of HRT (after 3 and 6 months of treatment of 112 women) the symptoms of climacteric syndrome and depression associated with the said syndrome based on the scales of Kupperman, Green, Hamilton and Beck as well as some selected parameters of metabolic state--concentration of foloculotropic hormonal profile FSH and 17 beta-estradiol E2, lipid profile (TC, HDL, LDL, TG-A) and glucose concentration. CONCLUSIONS: 1. The implementation of hormonal replacement therapy on 112 women made it possible to conclude that the treatment caused withdrawal of symptoms of climacteric syndrome and depression associated with the said syndrome. 2. Hormonal Replacement Therapy to a great extent had a beneficial influence on the lipid profile with 112 women after menopause especially as far as LDL is concerned. 3. HRT caused enormously significant increase in 17 beta-estradiol concentration and decrease of FSH concentration. 4. HRT statistically had no impact on glucose level with the study group of women.

Adult↗
PubMedDate not supplied

[Equine estrogens vs. esterified estrogens in the climacteric and menopause. The controversy arrives in Mexico].

It exists controversies about if the effects and benefits of the esterified estrogens could be similar to those informed for equines, because its chemical composition and bioavailability are different. Esterified estrogens has not delta 8,9 dehydroestrone, and its absorption and level of maximum plasmatic concentrations are reached very fast. In United States of America and another countries, esterified estrogens has been marketed and using for treatment of climacteric syndrome and prevention of postmenopausal osteoporosis, based on the pharmacopoiea of that country, but the Food and Drug administration (FDA) has not yet authorized up today, a generic version of conjugated estrogens. In Instituto Mexicano del Seguro Social (IMSS) and another institutions of health sector in Mexico, starting in year 2000, it has been used esterified estrogens for medical treatment of climacteric and menopausal conditions. For this reason, in this paper we revised the most recent information about pharmacology, chemical composition, clinical use and costs of the conjugated estrogens with the purpose to guide the decisions to purchase this kind of drugs in Mexican heath institutions.

Aged↗
PubMed2002

[Associated factors to depressive symptoms and somatic symptoms in climacteric women in the city of Temuco].

BACKGROUND: Depression is an important mental health problem. The Chilean Ministry of Health has considered depression in women as one of the health priorities for the country. AIM: To assess the prevalence of depressive and somatic symptoms and their risk factors in climacteric women. MATERIAL AND METHODS: A special questionnaire was applied to 171 women (45 to 55 years of age), coming from a community organization (PRODEMU) and a private health institution (ISAPRE Banmedica). Risk factors for depression were determined using multiple logistic regression. RESULTS: The prevalence of depressive symptoms was 43%. Women with primary education had an odds ratio for depression of 2.49, compared with women with high school or university education. Other risk factor for depression was the lack of a renumerated job (Odds ratio 1.9). The risk factors for somatic symptoms were the presence of depressive symptoms (OR 3.2), lack of secondary or university education (OR 2.4), low income (OR 1.9) and having a current partner (OR 3.6). CONCLUSIONS: There is a high prevalence of depressive symptoms in the studied population of climacteric women. Lack of education and of a renumerated job are important risk factors for the presence of such symptoms. Women with a low level of education and with depressive symptoms have also a high risk of presenting somatic symptoms.

Chile↗
PubMed1992

[Prostaglandins PGF2alpha in the fight against bleeding and hemorrhage the uterus during the climacteric period].

This article is about usage prostaglandins to fight against bleeding and haemorrhage from uterus in climacteric period. Prostaglandins are used widely by gynecologist and obstetrics as most powerful contracting drugs, namely in this situations when we observe returning, plentiful bleeding from uterus. Women with climacteric bleeding had administer prostaglandins intravenous or immediate intra-cervix. They are very good drug, strongly and a long time hold up bleeding. This method give us time to better preparing patients to operation and diminish losses of blood. Side effects are small and not trouble. Prostaglandins are very simply in usage and characterise very good haemostatic effect, recognised faster then in typical methods like hormonal, mechanical antifibrinolytic etc.

Climacteric↗
PubMedDate not supplied

[The relation between dysmenorrhea and hot flash in a group of women in climacteric].

Hot flushes in climacteric age can cause noticeable discomfort to those who have them. This functional disturbance confirms the strong relationship between the gonadic steroids and the central neurotransmitters. These complex mechanisms which control reproductive functions limit our knowledge of the pathogenesis of hot flushes. The possible intervention of prostaglandins in the rising of this disturbance and their participation in dismenorrhea have raised the hypothesis that the prostaglandins may be the common denominator in the development of dysmenorrhea in fertile age women and of hot flushes in climacteric age women. Under this context, we examined a number of women in menopause to determine if they suffered with dysmenorrhea in fertile age.

Adult↗
PubMed1992

Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.

Bone mass, calcium and lipid metabolism, climacteric symptoms, bleeding, blood pressure, and weight changes were studied in 62 healthy postmenopausal women at 3-month intervals throughout 2 years of treatment with continuous estradiol valerate (2 mg) plus cyproterone acetate (1 mg), sequential estradiol valerate (2 mg) plus levonorgestrel (75 micrograms), or placebo. During the 2 years of the study, bone mineral content of the distal and ultradistal regions of the forearm (measured by single-photon absorptiometry) remained unchanged in the hormone groups, whereas bone mineral content at these sites decreased by 5 and 6%, respectively, in the placebo group. Bone mineral density in the spine (measured by dual-photon absorptiometry and dual-energy x-ray absorptiometry) increased by 3-4% in the hormone groups and decreased by 2% in the placebo group. Biochemical estimates of bone turnover (serum alkaline phosphatase and fasting urinary calcium/creatinine) decreased significantly to premenopausal levels in the hormone groups, but remained unchanged in the placebo group. Serum concentrations of total and low-density lipoprotein cholesterol were significantly reduced by 5-10% (P less than .05-.01) in the estradiol + cyproterone acetate group and by 10-15% (P less than .001) in the estradiol valerate + levonorgestrel group. There were no significant changes in high-density lipoprotein cholesterol in the hormone groups. Virtually no changes were observed in the placebo group. Climacteric symptoms and hot flushes were significantly reduced in both hormone groups compared with the placebo group.(ABSTRACT TRUNCATED AT 250 WORDS)

Bone Density↗
PubMed1992

[Symptomatic profile of the climacteric female. Clinical experience].

UNLABELLED: To describe the symptoms of the climacteric female, 287 climacteric patients had their symptoms evaluated according to the criteria of Blatt-Kupperman for menopause. The median age was 50 years (P10 = 43 and P90 = 58). The main complaint was flushing in 46%, psychiatric symptoms in 17.8% a health examination in 14.6%, osteoporosis in 11.1%, menstrual problems in 6.3%, and other symptoms in 4.5%. Asthenia was a prominent symptom in 82% of patients, followed closely by headache, irritability and depression. Flushing was present in 77% of patients. Symptoms not usually associated to menopause, such as vertigo, palpitations and bone pain were quite prevalent. Only 69% of females were sexually active. Among them, 45% complained of dyspareunia and 58% of decreased or absent libido. The median Blatt index was 27. Working capacity was affected in 87% of patients. CONCLUSION: The menopausal period is associated to many symptoms which may motivate females to consult an internist.

Adult↗
PubMed2003

Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study.

OBJECTIVE: To assess the efficacy and tolerability of intravaginal rings (IVRs) delivering estradiol. DESIGN: This was a dose-escalating, continuous-dosing, pilot study. METHODS: Sixteen women post surgical menopause were recruited at a hospital-based menopause clinic. Over 20 weeks, each patient had IVR devices releasing 50, 75, 100, 150 and 200 mug/day of estradiol inserted consecutively at 4-weekly intervals. MAIN OUTCOME MEASURES: Climacteric symptoms were assessed, and levels of serum estradiol, lipoproteins and biochemical indices of bone turnover were estimated prior to insertion of the first IVR and at each monthly visit, when the IVR was changed to one of a higher dose. The susceptibility of low-density lipoprotein (LDL) to oxidation was assessed at 0, 12 and 20 weeks. RESULTS: Twelve women completed the study. The rings were well tolerated and serum estradiol levels increased in parallel with each increasing dose. Vasomotor and psychological symptoms and loss of libido were reduced by 76% (p < 0.001), 44% (p < 0.001) and 44% (p < 0.05), respectively, by the end of the study. There were no significant changes in levels of serum lipoproteins, although the ratio of LDL cholesterol to high-density lipoprotein cholesterol decreased by 7.2% (p = 0.01) after 20 weeks. The susceptibility of LDL to oxidation did not change. Urinary excretion of both calcium and deoxypyridinoline cross-links decreased significantly (p < 0.001), indicating a reduction in bone resorption. CONCLUSIONS: The rings were effective in controlling climacteric symptoms and had beneficial effects on bone metabolism, but no significant effects on lipoprotein levels or the susceptibility of LDL to oxidation.

Administration, Intravaginal↗
PubMed2003

[Laboratory study of the yi-fu-ning soft gelatin capsules in treating climacteric syndrome].

OBJECTIVE: To study the therapeutic mechanism of YFN on climacteric syndrome by investigating the effect of Yi-Fu-Ning soft gelatin capsules (YFN), which can nourish the kidney and activate blood, on serum sex hormone levels and hypothalamic monoamine transmitters contents in ovariectomized rats. METHOD: Fifty female mature Sprague-Dawley rats were randomly divided into 5 groups:sham operation;ovariectomy(OVX);OVX with diethylstilbestrol tablets(DT);OVX with YFN(high dose and low dose). After drugs had been given for 4 weeks, hypothalamic monoamine transmitters (NE, DA, 5-HT, 5-HIAA) contents were detected by fluorospectrophotometric method and serum sex hormone by radioimmunoassay. Adrenal gland index, uterus index and thymus index were also determined. RESULT: YFN could obviously improve serum E2 and increase adrenal gland and uterus index in OVX rats (P < 0.01 or P < 0.05). It could reduce hypothalamic 5-HT and 5-HIAA, which were increased in OVX rats(P < 0.01); It could also increase reduced NE and DA in OVX rats and reduce the ratio of 5-HT to NE and 5-HT to DA(P < 0.01). CONCLUSION: YFN can regulate procreate endocrine in various ways and ameliorate the function of hypothalamic monoamine neurotransmitter in OVX rats. So it can stabilize inner condition of body and relieve symptoms of climacteric syndrome.

Animals↗
PubMed2004

[Effect and tolerability of sequential administration of estradiol valerate and medroxyprogesterone acetate on menopausal symptoms, hormonal profile and biochemical markers in climacteric women].

UNLABELLED: Hormonal replacement therapy is the gold standard in the treatment and prophylaxis of menopausal symptoms and osteoporosis. THE AIM: Of the study was to assess changes in climacteric symptoms, hormonal profile and biochemical parameters during sequential hormonal replacement therapy in climacteric women 19 women aged 46-61 years old was included into the study. We evaluated Kuppermann's index, serum concentration of estradiol, FSH, morphology of the blood, lipids and haemostatic parameters. RESULTS: The menopausal symptoms significantly decreased. Lipids levels, haemostatic parameters and morphological parameters of the blood didn't change. CONCLUSION: The sequential hormonal replacement therapy with estradiol valerate and medroxy-progesterone acetate is efficient and safe.

Aged↗
PubMed2004

[Study on treatment of climacteric depression with bushen tiaogan qingxin recipe].

OBJECTIVE: To observe the effects of bushen tiaogan qingxin recipe (BTQR) on Hamilton rating scale for depression (HAMD), monoamine meurotransmitter and endocrinal function in patients with climacteric depression, and to explore its mechanism. METHODS: Patients were randomly divided into two groups, the 25 patients in the treated group treated with BTQR and 15 patients in the control group treated with hormone replacement therapy (HRT). The HAMD scoring, levels of 5-HT, NE in plasma, serum estradiol (E2), follicle-stimulating hormone (FSH), luteinizing hormone (LH) were determined before and after treatment, and the thickness of endometrium was measured by B-Doppler ultrasonographic technique. RESULTS: The total effective rate, evaluated by the HAMD score reducing rate, in the treated group was 87.2%, and in the control group was 67.3%, showing significant difference (P<0.05). After treatment, 5-HT decreased (P<0.01), NE increased (P<0.05) and 5-HT/NE ratio lowered (P<0.01) in the treated group; E2 increased in both groups; FSH, LH and FSH/LH ratio decreased in the treated group (P<0.05 or P<0.01), FSH/LH ratio decreased in the control group (P<0.05). The thickness of endometrium increased in the control group after treatment (P<0.05). CONCLUSION: The mechanism of BTQR in treating climacteric depression might be related with its actions in: (1) To regulate the synthesis and release of monoamine neurotransmitter; (2) To adjust reproductive endocrine function; (3) To coordinate the neuroendocrinal function.

Climacteric↗
PubMed2005

Acupuncture for treatment of climacteric syndrome--a report of 35 cases.

OBJECTIVE: To evaluate the effects of acupuncture for treatment of climacteric syndrome. METHODS: The 65 cases in this series were randomly assigned to the acupuncture group (N=35) and the control group (N=30), with the former treated by acupuncture and the latter by medication respectively. The therapeutic effects were evaluated by means of the clinical outcome, improvement in the symptom scores and the results of radioimmunoassays. RESULTS: In the acupuncture group, 12 cases were cured, 16 cases markedly effective, and 6 cases improved, the total effective rate being as high as 97.14%. The decrease in the symptom scores, and especially the elevation of the decreased E2 level and the decrease of the increased FSH and LH levels, demonstrated that acupuncture therapy was superior to medication. CONCLUSION: Acupuncture for regulating the mental activities and reinforcing the kidney is an effective therapy for climacteric syndrome.

Acupuncture Therapy↗
PubMedDate not supplied

[Climacteric symptomatology: relation with hormone levels and trophic features of the external genitalia].

During the last decade the development of a great amount of knowledge about the menopause has allowed to establish almost standardized hormonal treatments in order to prevent its symptoms and its late sequelae. Nevertheless, up to now the relationship between typical climacteric symptoms and the actual risk of late sequelae has not been assessed. The climacteric symptoms have hence been related to the involutional aspects of the external genitalia and to the levels of the sex steroids and gonadotropin hormones. An inverse relation between neuropsychical manifestations (insomnia, anxiety, depression, reduced memory, reduced libido) and 17-beta-oestradiol and progesterone levels has been shown. On the contrary, FSH and LH levels showed a direct relationship with neurovegetative symptoms. The relationship between the involutional aspects of the external genitalia and the atrophy related and the neuropsychical symptoms shows the need to evaluate these classes of symptoms, which appear to be most related to oestrogen and progesterone deprivation, in decision making toward hormonal replacement therapy.

Adult↗
PubMed1991

[History of the hormonal treatment of climacteric disease symptoms].

The first trials using oestrogen-containing substances to treat climacteric symptoms were performed as long ago as the end of the last century, when oestrogenic hormones were not yet even known to exist. However, it took a further 60 years or so before oestrogens and other sex hormones such as progestogens and androgens could be prepared in the form of acceptable hormonal drugs. Meanwhile, the use of such drugs and their artificial derivatives for the treatment of climacteric complaints and disorders and the prophylaxis of major postmenopausal diseases has been refined to such a high degree of safety and efficacy that these forms of therapy have become part of the essential medical armamentarium.

Austria↗
PubMed1990

Adjuvant effect of cavinton in the treatment of climacteric symptoms.

A comparative study has been performed in 40 climacteric, postmenopausal women. In the course of the examinations the results of two therapeutic methods were compared: hormone substitution therapy and combined hormone substitution and Cavinton adjuvant therapy. The improvement in the climacteric symptoms was measured by Kupperman's index and the results were statistically analysed. According to the results Cavinton significantly improves the changes in the symptoms to be obtained with oestrogen substitution. On the basis of the observations the author recommends the combination therapy. Cavinton did not cause side-effects which would have influenced the long-term use of the drug.

Adult↗
PubMed1990

[Pathogenesis of the climacteric syndrome].

In order to study the pathogenesis of climacteric syndrome, several experiments were carried out. The following results were found: (1) In 79 patients there were significant abnormal changes of nailfold microcirculation and vegetative nervous function. (2) Blood serotonin levels in 10 oophorectomized women were lower than those in the controls (P less than 0.05). (3)The plasma B-endorphin levels in 15 patients and the anti-B-endorphin antibody concentration in 19 patients with climacteric syndrome were also lower than those in the controls (P less than 0.01). These results suggest that the changes of serotonin and B-endorphin and its antibody in peripheral blood were perhaps related to the dysfunction of the vegetative nervous system and nailfold microcirculation, leading to the clinical symptoms in menopausal patients.

Autonomic Nervous System↗